Home / Brands / Rising Pharma Holding
Rising Pharma Holding Recalls
13 recalls on record · January 17, 2024 to July 29, 2026 · Drugs
Recalls by year
24
25
26
Count of recall notices naming this brand, by the year the recall was announced. A quiet year is not proof of a safe year.
July 29, 2026DrugsFDA
Rising Pharma Holding, Inc. recalls Rising, Cyproheptadine Hydrochloride Syrup, 2mg/5 mL, 473 mL (ONE PINT), Rx only, Manufactured for: Rising Pharma Holdin
Hazard: Presence of Precipitate: medication was crystallizing and particles floating in the bottle
March 11, 2026DrugsFDA
Rising Pharma Holding, Inc. recalls Product label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceutic
Hazard: Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing
October 22, 2025DrugsFDA
Rising Pharma Holding, Inc. recalls Carbidopa, Levodopa, Entacapone Tablets, 25 mg/100 mg/200 mg, 100-count bottle, Rx Only, Manufactured for: Rising Pharma
Hazard: Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).
March 26, 2025DrugsFDA
Rising Pharma Holding, Inc. recalls Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000-count bottle, Rx only, Distributed by: Rising Health, LLC, Saddle
Hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.
January 15, 2025DrugsFDA
Rising Pharma Holding, Inc. recalls Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC 57237-019-99) bottles; Distribu
Hazard: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
January 15, 2025DrugsFDA
Rising Pharma Holding, Inc. recalls Duloxetine Delayed-Release Capsules USP 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., E
Hazard: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
January 15, 2025DrugsFDA
Rising Pharma Holding, Inc. recalls Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000 count (NDC 57237-018-99) bottl
Hazard: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
December 11, 2024DrugsFDA
Rising Pharma Holding, Inc. recalls Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30), b) 90 count NDC 57237-019-90 and c) 1000 count (NDC 57
Hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
December 11, 2024DrugsFDA
Rising Pharma Holding, Inc. recalls Duloxetine Delayed-Release Capsules USP, 30 mg, a) 30 count (NDC 57237-018-30), b) 90 count (NDC 57237-018-90) and c) 10
Hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
December 11, 2024DrugsFDA
Rising Pharma Holding, Inc. recalls Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc.,
Hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
July 17, 2024DrugsFDA
Rising Pharma Holding, Inc. recalls Diflorasone Diacetate Ointment, USP, 0.05%, 60g tube, Rx only, Mfd. By: Lyne Laboratories, Inc., Brockton, MA 02301; Mfd
Hazard: Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification limit.
June 12, 2024DrugsFDA
Rising Pharma Holding, Inc. recalls Pregabalin Capsules 50mg, 1000-count bottle, Rx Only, Manufactured for: Rising Pharma Holdings, Inc., East Brunswick, NJ
Hazard: Presence of Foreign Tablets/Capsules: Complaint received from a re-packager, American Health Packaging (AHP), where a foreign tablet was discovered in one of the bottles during packaging set up. Tablet identified as pantoprazole tablet 20mg.
January 17, 2024DrugsFDA
Rising Pharma Holding, Inc. recalls buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx Only, Manufactured for: Rising Ph
Hazard: Presence of Foreign Tablets/Capsules